- Details
- (Length of Discussion: 4 min) Dr. Sanford J. Siegel, CEO of Chesapeake Urology, has always been an advocate and supporter of prostate cancer screening in men, especially those at high risk. Since 2006, under his leadership, Chesapeake Urology has provided free screenings to Maryland men, mostly in Baltimore City. In this video, Dr. Siegel shares his own prostate cancer story. Biographies: Sanford...
|
- Details
- Alicia Morgans and Joaquin Mateo discuss mapping the genomic landscape of advanced prostate cancer, and the realization that many patients with advanced forms of prostate cancer have tumors with defects in the repair of DNA damage. And what we observed for the first time is actually that a drug like olaparib, a PARP inhibitor, that has been used in breast or ovarian cancer, were associated to thes...
|
- Details
- (Length of Interview: 13 min) Charles Ryan and Gert Attard discuss what is currently being done with regards to serum analysis, plasma analysis, liquid biopsies, circulating tumor cells, in the field of prostate cancer. Biographies: Professor Gerhardt Attard MD Ph.D. FRCP Prof Attard is a John Black Charitable Foundation Endowed Chair in Urological Cancer Research at University College London. He...
|
- Details
- (Length of Presentation: 20 min) Neal Shore, MD, FACS interviews E. David Crawford on a forthcoming paper he authored titled, A ndrogen Receptor–Targeted Treatments for Prostate Cancer: 35 Years’ Progress with Anti-androgens . This paper takes the historical approach in reviewing the treatment of prostate cancer, where we started in the 60's, where we are today and where we hope to be in the futur...
|
- Details
- (Length of Discussion: 7 min) Charles Ryan and Carmel Pezaro have a conversation about Lutetium 177 PSMA based therapies in advanced prostate cancer. The experience she relates is unique to Australia leading to a difference in clinical options while presenting a potential conundrum with clinical trial designs. Biographies: Carmel Pezaro, MBChB, is a Senior Medical Oncologist and Senior Lecturer wo...
|
- Details
- (Length of Presentation: 9 min) Neal Shore, MD, FACS shares his 2018 AUA presentation on the groundbreaking PROSPER trial: chemotherapy-related endpoints in patients with nonmetastatic castration-resistant prostate cancer treated with enzalutamide. Meeting an unmet need in this Index 1 patient population with a goal of delaying time to metastasis has the potential to delay cancer-related morbidity...
|
- Details
- (Length of Video: 20 sec) M A Baky Fahmy illustrates concept about the presence of median raphe anomalies; mainly deviation as a clue for the expectation of megameatus with an intact prepuce. Biography: M A Baky Fahmy MD, FRCS, Professor of Pediatric Surgery, Editor-in-chief Journal of Pediatric Diseases Related Content: Penile Median Raphe Anomalies as an indicator of Megameatus Intact Prepuce An...
|
- Details
- (Length of Discussion: 4 min) An institutional database review of patients managed initially by a single urologist and followed over a 23-year period was performed by Scotland et al. This evaluation identified 80 patients with biopsy-proven low-grade Upper Tract Urothelial Carcinoma (UTUC) who had at least one lesion larger than 2 cm. Scotland and colleagues collected clinical data including demog...
|
- Details
- Andrew Armstrong and Alicia Morgans, discuss the PROPHECY trial, a prospective trial of circulating tumor cells, evaluating two current assays: the EPIC AR-V7 Nuclear Protein CTC and the Hopkins AR-V7 Adnatest. The conversation evolves to a discussion of the data from Armstrong's recent work shared at the 2018 ASCO GU meeting: measuring osteomimicry in three levels: RNA, DNA, and protein, potentia...
|
- Details
- Prostate cancer in African-American men remains a major public health issue. Judd W Moul, MD, reviews the history of the U.S. Preventive Services Task Force screening guidelines and highlights the US trends and patterns of disparities in cancer mortality among U.S. counties from 1980 to 2014. He touches on the molecular differences that may explain, in part, the aggressiveness of prostate cancer i...
|
